Prostate Cancer Daily

Rashid Sayyid and Zachary Klaassen review TALAPRO-3, a phase 3 trial of talazoparib plus enzalutamide versus placebo plus enzalutamide in 599 HRR-mutated metastatic androgen pathway modulation-sensitive prostate cancer patients.

Christopher Sweeney presents a Decipher® genomic classifier analysis of the ENZAMET trial, applying the 22-gene assay to determine which patients with metastatic hormone-sensitive prostate cancer benefit from adding docetaxel to ADT plus enzalutamide.